FUTURE OF HEALTHCARE,DIGITAL HEALTHCARE

MindMaze and Vibra Healthcare Partner to Deliver Advanced Digital Medicine and Neurorehabilitation Solutions for Patients from Clinic-to-Home

Vibra Healthcare | December 08, 2022 | Read time : 04:00 min

MindMaze and Vibra

MindMaze, a global pioneer in the development of AI-driven neurotechnology, and Vibra Healthcare, a leader in post-acute hospital patient care, are excited to announce a partnership to deploy MindMaze’s digital health technology platform in-clinic and at-home for patients within select Vibra hospitals in Kentucky and California as a first step. MindMaze’s digital neurotherapeutic solutions are designed to help patients regain function through digitally-enabled assessments as well as behavioral training of holistic motor, cognitive and cardiovascular systems following Stroke/TBI, SCI, Parkinsons Disease and other neurological indications. This innovative partnership will enable clinicians to provide patients in the clinic and at home with interventions at dosage and intensity levels that are orders of magnitude higher than the current standard of care.

MindMaze delivers novel software-based interventions and assessments for neurological diseases, as well as capabilities that monitor and measure patient function during the long-term management of chronic disease. The partnership will facilitate a large-scale roll-out of MindMaze solutions to improve care across in-patient, post-acute, community sub-acute and home-based care environments. The goal is to deliver a substantial increase in training and treatment for Vibra’s patients, as well as to offer seamless and coordinated transitions in care as patients are treated within the Vibra Healthcare System which operates and manages over 90 specialty hospitals as well as transitional care units/facilities in 19 states.

The need for solutions that deliver superior outcomes—as well as those that support patients during the lifetime of their chronic condition—has never been greater. Nearly 100 million Americans are afflicted by a neurological disease, as reported in the Annals of Neurology, resulting more often than not in costly disability that can worsen over time. Nearly 50% of the total health burden in the United States is due to morbidity and disability. Consolidated studies have demonstrated that high dose, high intensity training can improve outcomes in traditionally hard-to-treat neurological indications. MindMaze believes that multimodal technology is fundamental to address the growing challenges faced by clinicians, patients and caregivers alike.

MindMaze is committed to redefining neuro recovery across the continuum of care through the development evidence-driven solutions for patients with serious neurological conditions. We are focused on providing clinicians with powerful, digitally-enabled, cutting-edge tools, while also empowering patients and their families with easy-to-use, engaging and accessible solutions. In Vibra we have found a world-class partner with both the commitment and true capability to deliver a step-change in brain health as well as meaningful improvements in patient outcomes.”

Tej Tadi, Founder, Chairman & CEO of MindMaze

“Vibra is committed to delivering the best possible care for our patients and the best value for our customers,” said Brad Hollinger, Founder, Chairman and CEO of Vibra Healthcare. “Our facilities have consistently ranked among the top-rated hospitals and rehabilitation facilities in the country, and we are always looking for ways to improve upon our incredibly high standards. We strongly believe that innovative technology in AI is the pioneering path forward to dramatically improve patient outcomes in the most cost-effective way. MindMaze has impressed our team not just with the power of their technological capabilities, but also with their experience in deploying real-world care pathways for patients with Stroke and other neurological conditions in countries around the world.”

About MindMaze
Founded in 2012, MindMaze is a global leader in brain technology and digital neurotherapeutic solutions for brain health and recovery. With a presence in over 15 countries, its mission is to accelerate the brain’s ability to recover, learn and adapt. The company has two core divisions – Healthcare and Labs – working collaboratively at the intersection of neuroscience, bio-sensing, engineering, mixed reality and artificial intelligence. MindMaze Healthcare is advancing a universal platform for brain health with breakthrough solutions to some of the world’s most challenging problems in neurology, including stroke, Parkinson’s disease and Alzheimer’s disease. MindMaze Labs, the company’s R&D innovation hub, is focused on the future of human computing – working across multiple industries to innovate and build the next generation of human-machine interfaces. The company has offices in Lausanne, Baltimore, London, Paris and Mumbai. 

About the Vibra Healthcare
Vibra Healthcare, LLC is a post-acute care provider based in Mechanicsburg, PA that is focused on the development, acquisition, and operation of freestanding specialty care hospitals, medical rehabilitation hospitals, and outpatient physical rehabilitation centers. Teams of highly trained specialists lead clinical programs at Vibra’s specialty hospitals for rehabilitating patients who suffer from strokes, multiple traumas, major orthopedic, neurologic, cardiac, and respiratory conditions. Vibra and its affiliates currently employ over 10,000 employees and own, operate, and manage over 90 specialty hospitals, transitional care units/facilities, and hospital-based outpatient physical therapy locations in 19 states. 

Spotlight

The strategic case for change: Make quality our absolute priority, improving quality of care is our core purpose, Of greatest importance to all our stakeholders, Build on the excellent work already happening to improve quality, The need to focus on a more compassionate, caring service with patients first and foremost, More structured and bottom-up approach to improvement.

Spotlight

The strategic case for change: Make quality our absolute priority, improving quality of care is our core purpose, Of greatest importance to all our stakeholders, Build on the excellent work already happening to improve quality, The need to focus on a more compassionate, caring service with patients first and foremost, More structured and bottom-up approach to improvement.

Related News

DIGITAL HEALTHCARE, HEALTHCARE ANALYTICS

Long-Duration Ultrasound Treatment With sam® Elevates Regenerative Medicine Options for Patients

ZetrOZ Systems | December 13, 2022

Sustained Acoustic Medicine technology, the FDA-cleared ultrasound device created by ZetrOZ Systems, continues to demonstrate its ability to relieve pain and accelerate patients' return to sports, work and other daily activities. Now, medical professionals can administer the innovative technology as a pre- and post-treatment recovery option for regenerative medicine injectable treatments such as platelet-rich plasma and other autologous cellular-based therapies. PRP injections are safe, autologous blood products containing growth factors and cytokines with the potential to alter biological processes and support the three phases of tissue healing: inflammation, proliferation, and remodeling. PRP injections are commonly administered in the doctor's office multiple times over six to 12 months and may be painful to some patients. sam® offers a non-invasive, daily, home-use treatment option for pain and tissue remodeling, which is a powerful technology to complement PRP injections and other regenerative medicine therapies. "Sustained acoustic medicine is a powerful mechanobiological treatment modality," said Dr. George Lewis, founder and CEO of ZetrOZ Systems. "Each treatment increases vessel diameter to boost blood flow over several hours, accelerating tissue healing and delivering a significant reduction in pain for patients. The use of ultrasound and shockwave treatment in the clinical setting to complement rehabilitation and regenerative medicine is broadly used. sam® is the first long-duration ultrasound treatment available for prescription home use." The use of sam® is also continuing to expand in the professional sports medicine market, with ongoing use by 75% of professional and college affiliations, including the NFL, NBA, MLS, WBNA, MLB and the ACC. ZetrOZ Systems also partners with all professional sports organizations and sports medicine providers in Atlanta, GA, and are proud supporters of the healthcare and athletic training societies of the NFL, MLB, NHL, NBA and MLS. sam® treats over 35% of muscle and tendon injuries without surgery, helping elite athletes and professionals in physically demanding jobs get pain relief and natural healing. "Surgery is not always the best course of action for our athletes, and sam® technology offers a pathway to recovery without invasive surgery that can have risks and implications immediately or in the future," Lewis said. Ultrasound therapy continues to show promise, with more than 40 peer-reviewed studies showing that sam® offers faster healing after injury or surgery. These findings can empower care providers to offer this easy-to-use regenerative device that leads to better outcomes, happier patients, and lowers healthcare system costs. The technology can serve as a standalone treatment or adjunct to other treatment options for patients to stimulate soft-tissue repair. About ZetrOZ Systems ZetrOZ Systems is leading healing innovation in sports medicine, developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on proprietary medical technology of +46 patents. The exclusive manufacturer and developer of the sam® product line is designed for the treatment of acute and chronic musculoskeletal conditions.

Read More

FUTURE OF HEALTHCARE

CareView Communications Executes Agreement with New Hospital in Pensacola, FL

CareView Communications, Inc. | November 17, 2022

CareView Communications, Inc. an information technology provider to the healthcare industry, announced the signing of an agreement with a health system building a new campus in Pensacola, FL. The new campus includes a new acute care hospital and behavioral health unit with room for future expansion. The agreement calls for the installation of the CareView Patient Safety System®, which facilitates continuous remote patient monitoring for patients who may be at risk of harm due to falls, behavioral issues, or suicidal ideation. The CareView solution leverages an in-room camera with audio capabilities and patented Virtual Bed Rails® and Virtual Chair Rails® technologies to improve patient safety. The Virtual Rails use machine learning to identify when the patient's movement indicates a fall may be imminent, and subsequently alerts the Safety Technician. Pre-recorded messages or 2-way audio allow for direct communication with the patient. The System offers a considerable impact on sitter reduction and overall patient safety. “We are pleased to be working with our newest partner and know that our System is the solution to address their needs to reduce patient falls and increase patient safety.” Sandra McRee, CareView’s Chief Operating Officer About CareView Communications, Inc. As a leader in turnkey patient video monitoring solutions, CareView is redefining the standard of patient safety in hospitals and healthcare facilities across the country. For over a decade, CareView has relentlessly pursued innovative ways to increase patient protection, providing next-generation solutions that lower operational costs and foster a culture of safety among patients, staff, and hospital leadership. With installations in more than 150 hospitals, CareView has proven that its innovative technology is creating a culture of patient safety where patient falls have decreased by 80% with sitter costs reduced by more than 65%. Anchored by the CareView Patient Safety System, this modular, scalable solution delivers flexible configurations to fit any facility while significantly increasing patient safety and operational savings. All configurations feature HD cameras, high-fidelity 2-way audio/video, LCD displays for the ultimate in capability, flexibility, and affordability. Corporate offices are located at 405 State Highway 121 Bypass, Suite B-240, Lewisville, TX 75067.

Read More

FUTURE OF HEALTHCARE

Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease

Anumana | December 16, 2022

Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has entered into a multi-year agreement with Pfizer, Inc. for Anumana to develop an artificial intelligence electrocardiogram algorithm designed to enable the early suspicion of cardiac amyloidosis. Anumana will conduct a clinical validation trial and pursue De Novo classification for the algorithm as a Software-as-a-Medical-Device and aims to gain regulatory approval for the algorithm as an SaMD for the detection of cardiac amyloidosis in the U.S., Europe and Japan. Cardiac amyloidosis is a serious, progressive, and underdiagnosed rare disease that leads to heart failure.1 In patients with cardiac amyloidosis, the heart walls become stiff, making it difficult for the left ventricle to properly relax and fill with blood, while at the same time hampering its ability to squeeze and pump blood out of the heart. Symptoms and comorbidities associated with cardiac amyloidosis, such as shortness of breath, knee pain, bilateral carpal tunnel syndrome, kidney disease, and gastrointestinal issues, can vary and seem unrelated, making diagnosis difficult.2,3 “The challenge in diagnosing cardiac amyloidosis can prevent patients from getting treatment while the disease continues to progress. We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.” David McMullin, chief business officer of Anumana The research agreement with Pfizer will help deepen Anumana’s efforts to implement AI-enabled early detection software that can reveal signals from ECGs that humans cannot interpret. The ubiquitous nature of the painless, non-invasive 100-year-old ECG test gives AI-ECG algorithms the potential to reach a larger number of patients earlier. “AI-ECG solutions alert clinicians to humanly imperceptible patterns in ECG signals, providing an early warning for serious occult or impending disease,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Mayo Clinic Board of Advisors. “This stands to improve the lives of people with cardiac amyloidosis by improving the speed of triage and care of this group.” Anumana was founded in 2021 in collaboration with the Mayo Clinic Platform. Anumana has licensed Mayo Clinic AI-ECG algorithms for low ejection fraction, pulmonary hypertension, and hyperkalemia, all of which have received Breakthrough Device Designation from the U.S. FDA. These algorithms have been validated by over 75 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ventricular ejection fraction that was published in Nature Medicine in 2021, and another first of its kind batch enrolled prospective clinical impact study that demonstrated the effectiveness of AI-ECG to screen for undetected atrial fibrillation in normal sinus rhythm that was published in The Lancet in 2022. About Anumana Anumana, an AI-driven health technology company and portfolio company of nference, is harnessing industry-leading AI and translational science to unlock the electrical language of the heart as never before. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and other leading institutions to detect hidden diseases using AI-ECG algorithms and to enhance and improve interventional procedures through real-time AI techniques. Multiple Anumana algorithms have received FDA Breakthrough Device Designation and are currently undergoing rigorous clinical trial validation. Anumana software devices are designed for real-world physician use, integrating into existing workflows at the point of care to reduce costs and enhance quality of life. Anumana algorithms are investigational medical devices and have not yet received regulatory approval or clearance.

Read More